NCT07436741 2026-02-27Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerTianjin Medical University Cancer Institute and HospitalPhase 3 Not yet recruiting106 enrolled